Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCL161 + Topotecan in SCLC and Ovarian Cancer
NCT02649673Phase 1Terminated
- Sponsor
- SCRI Development Innovations
- Start
- Mar 2016
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LCL161 in small cell lung cancer (SCLC) and ovarian cancer, sponsored by SCRI Development Innovations. Primary endpoint: Incidence of Dose-Limiting Toxicities at 21 days. Started Mar 2016; status: terminated.
02
Drugs
LCL161
03
Conditions
small cell lung cancer (SCLC)ovarian cancer
Beyond the preview
Go deeper on NCT02649673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02649673.